Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study☆
Abstract
We explore the safety, and therapeutic benefit of intrathecal injection of ex-vivo expanded autologous bone marrow derived mesenchymal stem cells (BM-MSCs) in 10 patients with advanced multiple sclerosis (MS). Patients were assessed at 3, 6 and 12
months. Assessment at 3–6
months revealed Expanded Disability Scale Score (EDSS) improvement in 5/7, stabilization in 1/7, and worsening in 1/7 patients. MRI at 3
months revealed new or enlarging lesions in 5/7 and Gadolinium (Gd+) enhancing lesions in 3/7 patients. Vision and low contrast sensitivity testing at 3
months showed improvement in 5/6 and worsening in 1/6 patients. Early results show hints of clinical but not radiological efficacy and evidence of safety with no serious adverse events.
Keyword: Mesenchymal stem cells, Autologous, Intrathecal, Multiple sclerosis, Magnetic resonance imaging, Optical coherence tomography, Expanded disability status scale
To access this article, please choose from the options below
☆ This study was funded by intramural grants as well as grants from the “Azem and Saadeh” non-profit Lebanese organization. The university provided the equipment which is part of their property.
PII: S0165-5728(10)00326-7
doi:10.1016/j.jneuroim.2010.07.013
© 2010 Elsevier B.V. All rights reserved.
